Skip to main content
. 2016 Mar 30;7(18):26709–26723. doi: 10.18632/oncotarget.8489

Table 1. The IC50 of adriamycin and imatinib in K562, K562/ADM and the revertant K562/ADM cells.

IC50 K562 K562/ADM revertant K562/ADM
ADM(μg/ml) 0.465±0.04 26.56±0.43 17.56±0.53
imatinib(μM) 0.2±0.039 2.3±0.218 1.7±0.12